CORT
HEALTHCARECorcept Therapeutics Incorporated
AI Insight
What's Moving CORT Today?
No stock-specific AI insight has been generated for CORT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$28.66$91.00
$80.07
Fundamentals
Market Cap$8.6B
P/E Ratio227.7
EPS$0.35
Dividend Yield—
Dividend / Share—
ROE7.2%
Profit Margin6.2%
Debt / Equity—
Trading
Volume555K
Avg Volume (10D)—
Shares Outstanding107.4M
CORT News
58 articles- 3 Unpopular Stocks We Steer Clear OfYahoo Finance·Jun 23, 2026
- Alger Russell Innovation Index Updates for Second Quarter 2026Yahoo Finance·Jun 22, 2026
- Corcept Resubmits NDA for Relacorilant in Cushing's SyndromeYahoo Finance·Jun 18, 2026
- Corcept Therapeutics (CORT) resubmits FDA NDA for relacorilant in Cushing’s syndromeStock Titan·Jun 18, 2026
- Corcept Therapeutics (CORT) Stock After 114% YTD Surge Is The Rally JustifiedSimply Wall Street·Jun 18, 2026
- Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s SyndromeYahoo Finance·Jun 17, 2026
- Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law FirmTMX Newsfile·Jun 17, 2026
- June 2026's Leading Growth Stocks With Strong Insider OwnershipYahoo Finance·Jun 15, 2026
- Esquire Financial Holdings And 2 Insider Picks For Growth PotentialYahoo Finance·Jun 15, 2026
- Spotlight On June 2026's Insider-Favored Growth StocksYahoo Finance·Jun 12, 2026
- Korlym improves results for diabetes patients taking GLP-1 drugsCushing's Disease News·Jun 12, 2026
- 3 Growth Companies Insiders Are Betting OnYahoo Finance·Jun 12, 2026
- 3 Growth Companies With Insider Ownership Up To 23%Yahoo Finance·Jun 11, 2026
- Catalyst and Momentum Trials Data Fuels Optimism for Corcept Therapeutics (CORT)Yahoo Finance·Jun 11, 2026
- Insider Favorites: Top Growth Companies For June 2026Yahoo Finance·Jun 10, 2026
- Top Growth Companies With Insider Ownership In June 2026Yahoo Finance·Jun 10, 2026
- Corcept Therapeutics (CORT) Valuation After New Korlym CATALYST And MOMENTUM Trial DataSimply Wall Street·Jun 10, 2026
- ATRenew And Two Insider-Favored Growth Stocks To WatchYahoo Finance·Jun 9, 2026
- 3 Growth Stocks With High Insider Ownership And 29% Revenue GrowthYahoo Finance·Jun 9, 2026
- 3 Growth Companies With High Insider Ownership Seeing Up To 94% Earnings GrowthYahoo Finance·Jun 8, 2026
- CORT Stock Rises 42% in a Month: Here's What You Should KnowYahoo Finance·Jun 8, 2026
- Insider Favorites High Growth Companies June 2026Yahoo Finance·Jun 8, 2026
- Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®Yahoo Finance·Jun 6, 2026
- Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report?Yahoo Finance·Jun 5, 2026
- Growth Companies With High Insider Ownership And Up To 30% Return On EquityYahoo Finance·Jun 5, 2026
- Is It Too Late To Look At Corcept Therapeutics (CORT) After The Recent Share Price SurgeSimply Wall Street·Jun 5, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORTGlobeNewswire Inc.·Apr 21, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 21, 2026
- CORCEPT DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Corcept Therapeutics Incorporated Investors to Contact the Firm Regarding Their Rights Before April 21stGlobeNewswire Inc.·Apr 20, 2026
- CORT 3-DAY DEADLINE ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Approaching April 21st Lead Plaintiff Deadline in Securities Fraud Class Action Over Relacorilant FailureGlobeNewswire Inc.·Apr 19, 2026
- CORT DEADLINE ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action – CORTGlobeNewswire Inc.·Apr 18, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 17, 2026
- CORT Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline in Corcept Therapeutics Incorporated Securities Class Action Lawsuit — The Gross Law FirmGlobeNewswire Inc.·Apr 17, 2026
- CORT 1-WEEK DEADLINE ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Approaching April 21st Lead Plaintiff Deadline in Securities Fraud Class Action Over Relacorilant FailureGlobeNewswire Inc.·Apr 14, 2026
- Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated and Encourages Investors to Contact the FirmGlobeNewswire Inc.·Apr 13, 2026
- Corcept Therapeutics Incorporated Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – CORTGlobeNewswire Inc.·Apr 13, 2026
- INVESTOR DEADLINE: Corcept Therapeutics (CORT) Investors with Substantial Losses Have Opportunity to Lead the Corcept Class Action Lawsuit– Hagens BermanGlobeNewswire Inc.·Apr 10, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 10, 2026
- Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Corcept Therapeutics Incorporated (CORT), Lakeland Industries, Inc. (LAKE), and Navan, Inc. (NAVN) Announced by Holzer & Holzer, LLCGlobeNewswire Inc.·Apr 9, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Apr 7, 2026
Price Data
Open$80.03
Previous Close$79.71
Day High$82.31
Day Low$79.22
52 Week High$91.00
52 Week Low$28.66
52-Week Range
$28.66$91.00
$80.07
Fundamentals
Market Cap$8.6B
P/E Ratio227.7
EPS$0.35
Dividend Yield—
Dividend / Share—
ROE7.2%
Profit Margin6.2%
Debt / Equity—
Trading
Volume555K
Avg Volume (10D)—
Shares Outstanding107.4M
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—